A novel dipstick developed for rapid Bet V 1-specific IgE detection: recombinant allergen immobilized via a monoclonal antibody to crystalline bacterial cell-surface layers

The incidence of allergy to airborne proteins derived from tree and grass pollen, feces of mites, spores of molds, and pet dander has been increasing over the last decades. Since precise diagnosis is a prerequisite for successful immunotherapy, there is a rising demand for rapid, reliable, and inexpensive screening methods such as dipstick assays. With the purified recombinant major birch-pollen allergen rBet v la as model protein, crystalline bacterial cell-surface layers (S-layers) were tested for their applicability as an immobilization matrix for dipstick development. For this purpose, S-layers were deposited on a mechanically stable microporous support, eross-linked with glutaraldehyde, and free carboxylic acid groups of the S-layer protein were activated with carbodiimide. In the present test system, rBet v la was immobilized via the monoclonal mouse antibody BIP 1, which, unlike the allergen, is too large to enter the pores of the S-layer lattice, and which therefore formed a closed monolayer on the outermost surface of the crystal lattice. Moreover, BIP 1 is known to modulate IgE binding to the allergen. After incubation of the dipsticks in serum, washing of the reaction zone under tap water, and binding of an anti-IgE alkaline phosphatase conjugate, 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium was used as substrate, forming an IgE concentration-dependent colored precipitate on the S-layer surface. The investigation of patient sera previously tested with the CAP™ system confirmed the specificity of the S-layer-based dipstick assay. Since the dipstick is easy to handle and the whole test procedure takes only 90 min, this test system should be applicable for rapid determination of specific IgE and for first screening in the doctor's practice.     

Anatomical bases for a safe method of subclavian venipuncture

Summary Based on fundamental anatomical considerations which are explained in detail we developed a safe technique for the catheterization of the subclavian v.: the point of puncture, which is situated about 25 mm below the junction between the medial and the middle thirds of the clavicle, is accurately determined with the help of a pattern described in the paper. The needle is directed towards the palpable dimple between the spinous processes of the 6th and the 7th cervical vertebrae. The only structure the cannula can reach is the medial portion of the subclavian v. into which the catheter is inserted. Therefore pneumothorax, haemothorax or other incidents do not occur. The method was tested in 350 cases and proved to be absolutely free of complications.

---

Bases anatomiques pour une méthode sûre de ponction de la v. sub-clavière: expérience clinique sur 350 cas

Résumé En nous basant sur un travail anatomique fondamental détaillé dans une précédente publication, nous avons développé une technique sûre pour la ponction de la v. subclavière: le point de ponction qui se situe à peu près à 25 mm au-dessous du point de jonction entre le tiers médial et le tiers central de la clavicule est déterminé à l'aide d'un plan de construction décrit dans l'article. L'aiguille est dirigée vers la fossette palpable entre les apophyses épineuses de la 6e et de la 7e vertèbre cervicale. L'aiguille atteint directement la portion médiale de la veine dans laquelle le cathéter est introduit. Il ne peut donc y avoir ni pneumothorax ni aucun autre incident. Cette méthode a été testée dans 350 cas et n'a donné lieu à aucune complication.

     

丙型肝炎病毒母婴传播的研究

目的:研究丙型肝炎病毒(HCV)母婴传播机率及感染方式.方法:用ELISA和RT-PCR法检测母婴血清及母亲乳汁、羊水、唾液的抗-HCV IgG及HCV-RNA,循环测序法测定母婴HCV-cDNA序列.结果:对1 521例孕妇筛查,其中15例抗-HCV IgG阳性(12例HCV-RNA阳性).所生15例婴儿,随访结果仅1例抗-HCV IgG持续阳性,出生时2例血清HCV-RNA阳性者中的1例抗-HCV IgG及HCV-RNA持续阳性.HCV母婴传播率为16.7%(2/12).其中一对母婴间HCV-cDNA序列同源性为100%.羊水、乳汁、唾液抗-HCV及HCV-RNA检出率分别为100%和25.0%,53.5%和16.7%,100%和0.0%.结论:HCV母婴传播可能发生于宫内或分娩时,羊水可能是引起HCV母婴传播的重要因素,乳汁、唾液引起传播可能性较小.     

骨桥蛋白?CD44v6在胰腺癌中的表达及其与临床病理特征的关系

目的:探讨骨桥蛋白(OPN)与CD44v6在人胰腺癌中的表达,并分析OPN、CD44v6与胰腺癌临床病理特性的关系.方法:应用免疫组织化学方法检测OPN、CD44v6在43例胰腺癌、34例癌旁组织中的表达.结果:43例胰腺癌标本中OPN、CD44v6阳性表达率分别为65.1%、62.7%.34例胰腺癌旁组织OPN、CD44v6阳性表达率均为20.6%;有淋巴结转移的胰腺癌组织中OPN、CD44v6表达阳性率分别为86.7%、80.0%,无淋巴结转移者为53.5%、53.6%,二者相比差异均有显著性(P＜0.05);组织学分级为Ⅲ级的胰腺癌组织中CD44v6的表达率为85.7%,组织学分级为Ⅰ～Ⅱ级的胰腺癌组织中CD44v6的表达率为51.7%,二者相比差异有显著性(P＜0.05);CD44v6与OPN的表达呈正相关,相关系数r为0.446(P＜0.05).结论:OPN、CD44v6在胰腺癌的浸润、转移中可能起重要作用,它们可作为胰腺癌浸润、转移及评估预后的指标.     

电容漏电引起CT／eX线故障

从对故障代码所说明的故障信息进行分析入手，对故障机问题加以检修，供医学工程技术人员参考。     

来曲唑对大鼠子宫内膜α_vβ_3和HOXA10表达的影响

目的:探讨应用来曲唑促排卵对大鼠围着床期子宫内膜整合素αvβ3和HOXA10表达的影响。方法:将60只Wistar雌鼠随机等分为3组:来曲唑组(letrozole,LE组),克罗米芬组(clomiphenecitrate,CC组),生理盐水组(NS组),分别进行促排卵。用免疫组化法观察大鼠围着床期子宫内膜腺上皮整合素αvβ3的表达变化;应用RT-PCR和Westenblot方法观察大鼠围着床期子宫内膜HOXA10表达情况。结果:LE组大鼠子宫内膜αvβ3表达与NS组无差异(P>0.05),但LE组显著高于CC组(P>0.01);NS组HOXA10表达高于LE组(P>0.05),LE组HOXA10表达高于CC组(P>0.01)。结论:来曲唑促排卵对大鼠子宫内膜容受性的抑制作用比克罗米芬小,有可能成为较为合适的促排卵药物之一。     

钙粘附分子和CD44v6表达与膀胱移行细胞癌生物学特性的关系

目的　探讨钙粘附分子E cadherin(E CD)和CD44v6的表达与膀胱移行细胞癌发生及发展的关系。　方法　应用S P免疫组化染色法检测 96例膀胱移行细胞癌中E CD和CD44v6的表达。　结果　E CD和CD44v6阳性率分别为 :Ⅰ级 86 .7% (2 6 / 30 ) ,80 .0 % (2 4/ 30 ) ;Ⅱ级 5 2 .8% (19/ 36 ) ,6 9.4% (2 5 / 36 ) ;Ⅲ级 2 6 .7% (8/ 30 ) ,33 .3 % (10 / 30 )。E CD和CD44v6阳性率与膀胱移行细胞癌分级、分期 ,复发及生存率显著相关 (P <0 .0 1)。　结论　E CD和CD44v6阳性表达率与膀胱移行细胞癌生物学特性密切相关。     

Atypical Meigs’ syndrome in a neonate with ovarian torsion associated with an ovarian dermoid cyst

We describe a female neonate with ovarian torsion, ovarian follicular and dermoid cysts, congenital ascites, pleural effusions, and respiratory distress. Her symptoms were consistent with atypical Meigs syndrome and resolved after unilateral oophorectomy. This is the first report in a neonate of this syndrome in association with congenital ovarian disease.     

Plasma propofol concentrations during orthotopic liver transplantation

Objective: The aim of this study was to investigate the changes in plasma concentrations of propofol in three phases (the paleohepatic, anhepatic, and neohepatic phases) during orthotopic liver transplantation (OLT) using target‐controlled infusion (TCI). Methods: Ten patients undergoing OLT without venovenous bypass were studied (age 29–53 years, weight 56–79 kg). After intubation, a non‐hypnotic target concentration of propofol 0.5 µg ml^?1 using a Diprifusor^® pump (Zeneca Pharmaceuticals, Macclesfield, UK) was administered as a supplement anesthesia throughout the procedure. Plasma samples were obtained in each phase for propofol assay, respectively. Performance parameters for the Diprifusor^® system in each phase, the percentage median performance error (MDPE), the percentage median absolute performance error (MDAPE), and the percentage median absolute constancy error (MDACE) were evaluated. Results: In all patients, measured plasma propofol concentrations were several times higher than Diprifusor^® values in each phase during the procedure. In nine patients, propofol concentrations in the anhepatic phase were higher than those in the paleohepatic or neohepatic phase (P < 0.05). There were no significant differences between the paleohepatic and neohepatic phases. Interindividual variation of the plasma propofol concentrations was significant (P < 0.05). Percentage median performance error of Diprifusor^® in each phase, as well as MDAPE, was large (>300%) and was significantly higher in the anhepatic phase (P < 0.01), whereas MDACE was relatively small and there was no significant difference between phases. Conclusions: Models used by Diprifusor^® are not suitable for liver transplantation patients. A further study should be performed in order to determine all pharmacokinetic parameters of propofol in these patients.